Insilico Medicine nominates orally available pre-clinical candidate targeting NLRP3 to treat inflammation and central nervous system diseases
As the first line against microbial infections or endogenous cellular damage in our body, the innate immune system utilizes NLRs (NOD-like receptors) to sense the molecules triggering microbial infection and damage, thus ensuring the proper immune response function. In the NLRs family, NLRP3 is the most characterized member, and its overactivation can lead to excessive production of pro-inflammatory cytokines and chemokines, driving pathological processes in various inflammatory diseases.
CAMBRIDGE, Mass., Dec 10, 2024 --- Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery ...















